OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
Capital One Says AML Review Led to Closure of Trump Organization Accounts 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
Nike China Strategy to Lift Margins Despite $1 Billion Sales Hit, Bernstein Says 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
MENLO PARK, Calif., April 20, 2018 -- Pacific Biosciences of California, Inc. (NASDAQ:PACB) will hold its quarterly conference call to discuss its First Quarter 2018 Financial Results on Wednesday, May 2, 2018, at 4:30pm Eastern Time.
The call will be webcast and may be accessed at Pacific Biosciences’ website at: http://investor.pacificbiosciences.com/.
Date: May 2, 2018
Time: 4:30pm ET
Listen via Internet: http://investor.pacificbiosciences.com/
Toll-free: 888.366.7247
International: 707.287.9330
Conference ID: 2187939
Replay: http://investor.pacificbiosciences.com
About Pacific Biosciences
Pacific Biosciences of California, Inc. (NASDAQ:PACB) offers sequencing systems to help scientists resolve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT®) technology, Pacific Biosciences’ products enable: de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms in important gene families, and find novel genes; targeted sequencing to more comprehensively characterize genetic variations; and real-time kinetic information for epigenome characterization. Pacific Biosciences’ technology provides high accuracy, ultra-long reads, uniform coverage, and the ability to simultaneously detect epigenetic changes. PacBio® sequencing systems, including consumables and software, provide a simple, fast, end-to-end workflow for SMRT Sequencing. More information is available at www.pacb.com.
Contact: Pacific Biosciences
Trevin Rard
650.521.8450
[email protected]
